Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT04255108 · ClinicalTrials.gov registry record
Validation of a Sensor for Non-invasive Measurement of Stroke Volume and Cardiac Output
A clinical trial, sponsored by Baxter Healthcare Corporation.
- Completed
- Registry status
- 50
- Enrollment target
NCT04255108: Completed study, sponsored by Baxter Healthcare Corporation.
NCT04255108 is a clinical trial that has completed, run by Baxter Healthcare Corporation. The registered enrollment target is 50 participants. According to ClinicalTrials.gov, the official US trial registry.
The verdict
NCT04255108 has completed, sponsored by Baxter Healthcare Corporation.
- COMPLETED
- Registry status
- 50 participants
- Enrollment target
Study Summary
toSense, Inc. has developed a novel, non-invasive, body-worn sensor -CoVa Patch-that offers an alternative to invasive continuous cardiac output monitoring. To validate this new sensor's measurements of stroke volume and cardiac output, toSense, Inc. will conduct a study that compares its measurement performance to that from a pulmonary artery catheter using the thermodilution method.
Primary Outcome
The primary objective of this study is to validate stroke volume (the amount of blood pumped by the left ventrical of the heart in one contraction) measurements made using CoVa Patch to those made using a pulmonary artery catheter and the thermodilution method. Thermodilution requires a pulmonary artery catheter and are calculated by a monitoring system based on temperature changes in the heart when a cooler solution is injected into the right atrium via the proximal port of a pulmonary artery
Interventions
- DEVICE Cova Patch
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 50 participants |
| Start Date | 2020-02-19 |
| Est. Completion | 2020-04-09 |
What the finished NCT04255108 record still lists
NCT04255108 is an observational study that tracks outcomes without assigning an intervention. The registry caps enrollment at 50 participants, a relatively small participant target.
The record links to 0 conditions, and to 1 intervention - of which Cova Patch is the first listed.
NCT04255108 does not publish any study locations in the registry export this page uses.
Frequently Asked Questions
What is clinical trial NCT04255108 about?
NCT04255108 is a clinical study titled "Validation of a Sensor for Non-invasive Measurement of Stroke Volume and Cardiac Output". toSense, Inc. has developed a novel, non-invasive, body-worn sensor -CoVa Patch-that offers an alternative to invasive continuous cardiac output monitoring. To validate this new sensor's measurements of stroke volume and cardiac output, toSense, Inc. will conduct a study that compares its measuremen...
What is the current status of trial NCT04255108?
This trial is currently completed. The enrollment target is 50 participants. The study started on 2020-02-19. Estimated completion is 2020-04-09.
What interventions are being tested in trial NCT04255108?
The interventions under investigation include: Cova Patch (DEVICE).
Who is sponsoring clinical trial NCT04255108?
This trial is sponsored by Baxter Healthcare Corporation, which has 46 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Nationwide trials with similar profiles
Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.
Similar enrollment target
- NCT00200889 · 50 participants · Early Phase 1
Mapping Auricular Vagus Nerve Circuitry
- NCT00409435 · 50 participants · Phase 2
A Study of Pyridostigmine in Postural Tachycardia Syndrome
- NCT01202305 · 50 participants
The Use of Lymph Node Biopsies to Support HIV Pathogenesis Studies
- NCT01225913 · 50 participants · Phase 4
Mechanism(s) of Airflow Limitation During Exacerbation of Asthma
Similar registry start date
- NCT05962346 · started 2026-12 · NA
Fetal Endoscopic Tracheal Occlusion for Congenital Diaphragmatic Hernia
- NCT07125183 · started 2026-12 · Phase 2
Study on Efficacy and Tolerability of Weekly Doxorubicin in Elderly Patients With Advanced or Metastatic Leiomyosarcoma
- NCT07292298 · started 2026-11 · Phase 2
Phase 2 Single-Arm Rectal Cancer Brachytherapy for Patients With Low-Lying Residual Adenocarcinoma After Total Neoadjuvant Therapy to Improve Organ Preservation Rates
- NCT04263285 · started 2026-10 · NA
Treatment of Depression Post-SCI